CDP-diacylglycerol--inositol 3-phosphatidyltransferaseGenealiases: PIS · PIS1
Q-omics provides the consensus-scored CDIPT profile across patient tissues and cancer cell-line models. CDIPT expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, CDIPT is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, CDIPT protein abundance shows 33,396 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight COAD, HNSC, and BRCA as cancer lineages where CDIPT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDIPT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDIPT survival associations across molecular data types. CDIPT RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDIPT RNA expression–survival associations across cancer types. High CDIPT expression shows unfavorable associations in COAD, HNSC and BLCA, but favorable associations in KIRC, UVM and CESC. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for CDIPT RNA expression.
This table summarizes CDIPT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 11. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CDIPT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDIPT shows lower tumor expression in UCEC and KICH and higher tumor expression in HNSC, KIRC, KIRP and LIHC. The HNSC box plot shows higher CDIPT RNA expression in tumor versus normal tissue (log2 FC = +0.921, t-test p < 0.001).
This table shows molecular features associated with CDIPT in patient tissues and cancer cell lines. In patient samples, CDIPT shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, CDIPT RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in OVARY and UPPER_AERODIGESTIVE_TRACT.
